EX-10.53



 Exhibit 10.53 

EXECUTIVE EMPLOYMENT 

AGREEMENT BY AND BETWEEN 

HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND 

SHAO-LEE LIN 

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between
Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Rd, Lake Forest IL 60045, (hereinafter referred to together
as the “Company”) and Shao-Lee Lin (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing January 4, 2018
(the “Effective Date”). 
 RECITALS 

WHEREAS, the Company desires assurance of association and services of the Executive in order to retain the Executive’s experience,
skills, abilities, background and knowledge, and is willing to engage the Executive’s services on the terms and conditions set forth in this Agreement; and 

WHEREAS, Executive desires to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set
forth in this Agreement. 
 AGREEMENT 
  

	1.	Employment. 

 1.1    Term. The Company hereby agrees to
employ the Executive, and the Executive hereby accepts employment by the Company, upon the terms and conditions set forth in this Agreement. Executive’s employment shall be governed under the terms set forth in this Agreement beginning on the
Effective Date and shall continue until it is terminated pursuant to Section 4 herein (hereinafter referred to as the “Term”). 

1.2    Title. From and after the Effective Date the Executive will have the title of Executive Vice
President, Head of Research and Development and Chief Scientific Officer (such position held by Executive during such period is hereinafter referred to as “EVP CSO”) and Executive shall serve in such other capacity or
capacities commensurate with her position as EVP CSO as the President and CEO of the Company may from time to time prescribe. 

1.3    Duties. The Executive shall do and perform all services, acts or things necessary or advisable to
manage and conduct the business of the Company and shall have the authority and responsibilities which are generally associated with the position of EVP CSO. The Executive shall report to the President and CEO. 

1.4    Policies and Practices. The employment relationship between the Parties shall be governed by this
Agreement and the policies and practices established by the Company and the Board of Directors (hereinafter referred to as the “Board”). In the event that the terms of this Agreement differ from or are in conflict with the
Company’s policies or practices or the Company’s Employee Handbook, this Agreement shall control. 

  
 1. 








 1.5    Location. The Executive shall perform the services the
Executive is required to perform pursuant to this Agreement in at the Company’s U.S. Headquarters in Lake Forest Illinois. The Company may from time to time require the Executive to travel temporarily to other locations outside of Lake Forest,
Illinois area in connection with the Company’s business. 
  

	2.	Loyalty of Executive. 

 2.1    Loyalty. During the
Executive’s employment by the Company, the Executive shall devote the Executive’s business energies, interest, abilities and productive time to the proper and efficient performance of Executive’s duties under this Agreement. Subject
to the prior written consent of the President and CEO, the Executive is permitted to serve on the board of directors of one other company, so long as the other company does not compete with the Company. 

2.2    Exclusive Employment. Except with the prior written consent of the Chief Executive Officer, Executive
shall not, during the term of this Agreement, undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in any civic and not-for-profit activities so long as such activities do not materially interfere with the performance of her duties hereunder or present a conflict of interest with the
Company. 
 2.3    Agreement not to Participate in Company’s Competitors. During the Term of this
Agreement, the Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise
or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. Notwithstanding the foregoing, Executive may invest and/or maintain investments in any public or private
entity up to an amount of 2% of an entity’s fully diluted shares and on a passive basis. 
  

	3.	Compensation to Executive. 

 3.1    Base Salary. The
Company shall pay the Executive a base salary at the initial annualized rate of six hundred twenty five thousand dollars ($625,000.00) per year, subject to standard deductions and withholdings, or such higher rate as may be determined from time to
time by the Board or the compensation committee thereof (hereinafter referred to as the “Base Salary”). Such Base Salary shall be paid in accordance with the Company’s standard payroll practice. Payments of salary
installments shall be made no less frequently than once per month. Executive’s Base Salary will be reviewed annually each December and Executive shall be eligible to receive a salary increase (but not decrease) annually in an amount to be
determined by the Board or the compensation committee thereof in its sole and exclusive discretion. Once increased, the new salary shall become the Base Salary for purposes of this Agreement and shall not be reduced without the Executive’s
written consent. Any material reduction in the Base Salary of the Executive, without her written consent, may be deemed Good Reason as set forth in and subject to Section 4.5.2 of this Agreement. 

  
 2. 








 3.2    Sign-On Bonus.
Executive shall be entitled to a one time sign on bonus equal to seven hundred forty thousand dollars ($740,000) (hereinafter referred to as the “Sign On Bonus”), subject to standard deductions and withholdings. The Sign On
Bonus shall be paid to Executive as follows: (1) six hundred thousand dollars ($600,000) paid on or before January 15, 2018; and (2) one hundred forty thousand dollars ($140,000) paid on or before January 15, 2019, provided that
Executive is still an employee of Company on January 15, 2019. If Executive’s employment is terminated by Company for “Cause,” as defined in section 4.5.3 of this Agreement, or if Executive provides notice to
Company of her intent to terminate this Agreement Without Good Reason, as described in section 4.2.2 of this Agreement (each hereafter referred to as a “Termination Event,” Executive shall reimburse Company one hundred
percent (100%) of any payments made in accordance with the terms of this Section 3.2, if such Termination Event occurs during the same calendar year in which the payment is made, and fifty percent (50%) of any payment if such Termination Event
occurs during the calendar year immediately following the calendar year in which such payment is made. Any reimbursement payments provide required under this Section 3.2 shall be due within 15 days of the applicable Termination Event. After the
calendar year immediately following the calendar year in which such payment is made (which date is no longer than two (2) years from the date of the initial payment), the Employee does not have to reimburse the Company for any reason. 

3.3    Exit Payment. Executive shall also be eligible for a payment of an amount equal to the amount
Executive is required to pay her former employer due to resignation from her prior employment, but in no case shall this amount exceed seventy five thousand dollars ($75,000). 

3.4    Discretionary Bonus. Provided the Executive meets the conditions stated in this Section 3.4, the
Executive shall be eligible for an annual discretionary bonus (hereinafter referred to as the “Bonus”) with a target amount of sixty percent (60%) of the Executive’s Base Salary, not to exceed two hundred percent (200%)
of Executive’s Base Salary„ subject to standard deductions and withholdings, based on the Board’s determination, in good faith, and based upon the Executive’s individual achievement and company performance objectives as set by
the Board or the compensation committee thereof, of whether the Executive has met such performance milestones as are established for the Executive by the Board or the compensation committee thereof, in good faith, in consultation with the Executive
(hereinafter referred to as the “Performance Milestones”). The Performance Milestones will be based on certain factors including, but not limited to, the Executive’s performance and the Company’s financial
performance. The Executive’s Bonus target will be reviewed annually and may be adjusted by the Board or the compensation committee thereof in its discretion, provided however, that the Bonus target may only be materially reduced upon
Executive’s written consent. The Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions thereof. The Bonus shall be paid during the calendar year following the performance
calendar year. 
 3.5    Equity Awards. As an inducement to the Executive’s commencement of
employment with the Company, and subject to approval by the Compensation Committee, the Executive will be granted the following equity awards as “Inducement Awards” pursuant to and subject to the terms of the Horizon Pharma
Public Limited Company 2014 Equity Incentive Plan (“2014 Equity Incentive Plan”) and its form of stock option and restricted stock unit award agreements, in the forms to be provided to Executive (collectively the
“Equity Plan Documents”) and compliance with applicable securities laws: 

  
 3. 








 3.5.1    Inducement Option. A stock option to purchase ordinary
shares of Horizon Pharma plc with a fair value of $1,100,000 as of January 4, 2018 (the “Option”). The number of ordinary shares subject to the Option will be calculated based on the fair value of the Option determined
under the Black-Scholes Method as of January 4, 2018. The Option will have an exercise price equal to the closing price of Horizon Pharma plc’s ordinary shares on the applicable date of grant, which will be January 4, 2018 (the
“Vesting Commencement Date”). All options will be issued as nonstatutory stock options. Subject to Executive’s continued provision of services to the Company through the applicable vesting dates, the Option shall vest as
follows: 25% of the total number of shares subject to the Option shall vest on the first anniversary of the Vesting Commencement Date or January 4, 2019 and 1/36 of the remaining number of shares subject to the Option shall vest on each monthly
anniversary thereafter so that the Option would fully vest on the four (4) year anniversary of the Vesting Commencement Date subject to Executive’s continued services with the Company through such date. 

3.5.2    Inducement RSU. A restricted stock unit award in respect of number of ordinary shares of Horizon
Pharma plc having a fair value of $1,100,000 as of January 4, 2018, which will be the applicable date of grant (the “RSU Award”). Subject to Executive’s continued provision of services to the Company through the
applicable vesting dates, the RSU Award shall vest as follows: 25% of the total number of units subject to the RSU Award shall vest on the first anniversary of the Vesting Commencement Date, and thereafter 25% of the total number of units subject to
the RSU Award shall vest on each anniversary thereafter, so that the RSU Award would fully vest on the fourth anniversary of the Vesting Commencement Date, subject to Executive’s continued services with the Company through such date. 

3.5.3    Annual Long Term Incentive Plan. As of January 4, 2018 Executive will participate in the
Annual Long-Term Incentive Plan (“ALTIP”) currently under development by the Board of Directors for executives, subject to adoption of the ALTIP by the Board of Directors and all applicable terms which may apply. The annual
grant for the Executive is anticipated to be between $2.0M—$2.7M in a mix of RSUs and PSUs. The final target amount, vesting schedule and other terms and criteria for the ALTIP are expected to be determined by the Board of Directors in late
December 2017 and may be subject to shareholder approval. 
 3.5.4    Legal Review. Upon the
Executive’s submission of appropriate itemized proof and verification of reasonable and customary legal fees incurred by the Executive in obtaining legal advice associated with the review, preparation, approval, and execution of this Agreement,
the Company shall pay for up to $10,000.00 of such legal fees subject to receipt of appropriate proof and verification of such legal fees no later than sixty (60) days of receipt of an invoice for legal services from the Executive and/or her
attorneys. To be eligible for reimbursement, the invoice must be submitted no later than ninety (90) days after the legal fees are incurred. 

3.6    Changes to Compensation. The Executive’s compensation may be changed from time to time by mutual
agreement of the Executive and the Company. In the event that the Executive’s base salary is materially decreased without her written consent, said decrease will be Good Reason for the Executive to terminate the Agreement as set forth in and
subject to Section 4.5.2 of this Agreement. 

  
 4. 








 3.7    Taxes. All amounts paid under this Agreement to the
Executive by the Company will be paid less applicable tax withholdings and any other withholdings required by law or authorized by the Executive. 

3.8    Benefits. The Executive shall, in accordance with Company policy and the terms of the applicable plan
documents, be eligible to participate in benefits under any executive benefit plan or arrangement which may be in effect from time to time and made available to the Company’s executives or key management employees, provided, however, that the
Executive shall be entitled to at least four (4) weeks of paid vacation annually. 
  

	4.	Termination. 

 4.1    Termination by the Company. The
Executive’s employment with the Company may be terminated only under the following conditions: 

4.1.1    Termination for Death or Disability. The Executive’s employment with the Company shall
terminate effective upon the date of the Executive’s death or “Complete Disability” (as defined in Section 4.5.1), provided, however, that this Section 4.1.1 shall in no way limit the Company’s obligations
to provide such reasonable accommodations to the Executive and/or her heirs as may be required by law. 

4.1.2    Termination by the Company For Cause. The Company may terminate the Executive’s employment
under this Agreement for “Cause” (as defined in Section 4.5.3) by delivery of written notice to the Executive specifying the Cause or Causes relied upon for such termination, provided that such notice is delivered within
two (2) months following the occurrence or discovery of any event or events constituting “Cause”. Any notice of termination given pursuant to this Section 4.1.2 shall effect termination as of the date of the notice
or such date as specified in the notice. The Executive shall have the right to appear before the CEO before any termination for Cause becomes effective and binding upon the Executive. 

4.1.3    Termination by the Company Without Cause. The Company may terminate the Executive’s employment
under this Agreement at any time and for any reason or no reason subject to the requirements set out in Section 4.4 of this Agreement. Such termination shall be effective on the date the Executive is so informed or as otherwise specified by the
Company, pursuant to notice requirements set forth in Section 6 of this Agreement. 
 4.2    Termination
By The Executive. The Executive may terminate her employment with the Company at any time and for any reason or no reason, including, but not limited, to the following conditions: 

4.2.1    Good Reason. The Executive may terminate her employment under this Agreement for “Good
Reason” (as defined below in Section 4.5.2) by delivery of written notice to the Company specifying the Good Reason relied upon by the Executive for such termination in accordance with the requirements of such section. 

  
 5. 








 4.2.2    Without Good Reason. The Executive may terminate the
Executive’s employment hereunder for other than Good Reason upon thirty (30) days written notice to the Company. 

4.3    Termination by Mutual Agreement of the Parties. The Executive’s employment pursuant to this
Agreement may be terminated at any time upon a mutual agreement in writing of the Parties. Any such termination of employment shall have the consequences specified in such mutual agreement. 

4.4    Compensation to Executive Upon Termination. In connection with any termination of the
Executive’s employment for any reason, the Executive or the Executive’s estate, as applicable, shall be entitled to any amounts payable to the Executive or the Executive’s beneficiaries subject to and accordance with the terms of the
Company’s employee welfare benefit plans or policies (excluding any severance pay). 
 4.4.1    Death or
Complete Disability. If the Executive’s employment shall be terminated by death or Complete Disability as provided in Section 4.1.1, the Company shall pay to Executive, and/or Executive’s heirs, all earned but unpaid Base Salary,
any earned but unpaid discretionary bonuses for any prior period at such time as bonuses would have been paid if the Executive remained employed, all accrued but unpaid business expenses, and all accrued but unused vacation time earned through the
date of termination at the rate in effect at the time of termination (hereinafter referred to as the “Accrued Amounts”), less standard deductions and withholdings. The Executive shall also be eligible to receive a pro-rated bonus for the year of termination, as determined by the Board or the Compensation Committee of the Board based on actual performance and the period of the year she was employed (hereinafter referred to as
the “Pro-rata Bonus”), less standard deductions and withholdings, to be paid as a lump sum within thirty (30) days after the date of termination. 

4.4.2    With Cause or Without Good Reason. If the Executive’s employment shall be terminated by the
Company for Cause, or if the Executive terminates employment hereunder without Good Reason, the Company shall pay the Executive’s Base Salary, accrued but unpaid business expenses and accrued and unused vacation benefits earned through the date
of termination at the rate in effect at the time of termination, less standard deductions and withholdings. 

4.4.3    Without Cause or For Good Reason. 

(i)    Not in Connection With a Change in Control. If the Company terminates the Executive’s
employment without Cause or the Executive terminates her employment for Good Reason, and Section 4.4.3(ii) below does not apply, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum
no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company an executed waiver and release of claims (the form of which
is attached hereto as Exhibit A) (the “Release”) within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become
effective in accordance with its terms (the “Release Effective Date”), and subject to Executive entering into 

  
 6. 








 
no later than the Release Effective Date a non-competition agreement to be effective during the Severance Period (as defined below), substantially similar
to Section 2.3, and continuing to abide by its terms during the Severance Period, the Executive shall be entitled to: 

(a)    the equivalent of the Executive’s Base Salary in effect at the time of termination will continue to be
paid for a period of twelve (12) months following the date of termination (hereinafter referred to as the “Non Change in Control Severance Period”), less standard deductions and withholdings, to be paid during the Non
Change in Control Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; and 

(b)    in the event the Executive timely elects continued coverage under COBRA, the Company will continue to pay
the same portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the qualifying family
members of the Executive, following the date of termination up until the earlier of either (i) the last day of the Non Change in Control Severance Period or, (ii) the date on which the Executive begins full-time employment with another
company or business entity which offers comparable health insurance coverage to the Executive (such period, the “Non Change in Control COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its
sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the
Company shall in lieu thereof pay Executive a taxable cash amount, which payment shall be made regardless of whether the Executive or her qualifying family members elect COBRA continuation coverage (the “Health Care Benefit
Payment”). The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health
Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration
of the Non Change in Control COBRA Payment Period. 
 (ii)    In Connection With a Change in Control. If
the Company (or its successor) terminates the Executive’s employment without Cause or the Executive terminates her employment for Good Reason within the period commencing three (3) months immediately prior to a Change in Control of the
Company and ending eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the Executive shall receive the Accrued Amounts subject to standard deductions and
withholdings, to be paid as a lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company (or its successor) an
executed Release within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance with its terms, and subject to
Executive entering into no later than the Release Effective Date a non-competition agreement to be effective during the Severance Period, substantially similar to Section 2.3, and continuing to abide by
its terms during the Severance Period, then in lieu of (and not additional to) the benefits provided pursuant to Section 4.4.3(i) above, the Executive shall be entitled to: 

  
 7. 








 (a)    the equivalent of the Executive’s Base Salary in effect
at the time of termination will continue to be paid for a period of eighteen (18) months following the date of termination (hereinafter referred to as the “Change in Control Severance Period”), less standard deductions
and withholdings, to be paid during the Change in Control Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; 

(b)    one and half (1.5) times Executive’s target Bonus in effect at the time of termination, or if none,
one and half (1.5) times the last target Bonus in effect for Executive, less standard deductions and withholdings, to be paid in a lump sum within ten (10) days following the later of (i) the Release Effective Date, or (ii) the
effective date of the Change in Control; and 
 (c)    in the event the Executive timely elects continued
coverage under COBRA, the Company will continue to pay the same portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that
Company paid for benefits to the qualifying family members of the Executive, following the date of termination until the expiration of the Change in Control Severance Period. Notwithstanding the foregoing, if the Company determines, in its sole
discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company
shall in lieu thereof pay Executive the Health Care Benefit Payment, which payment shall be made regardless of whether the Executive or her qualifying family members elect COBRA continuation coverage. The Health Care Benefit Payment shall be paid in
monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company
otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the Change in Control Severance Period. 

(iii)    No Duplication of Benefits. For the avoidance of doubt, in no event will Executive be entitled to benefits under
Section 4.4.3(i) and Section 4.4.3(4 If Executive commences to receive benefits under Section 4.4.3(i) due to a qualifying termination prior to a Change in Control and thereafter becomes entitled to benefits under
Section 4.4.3(4), any benefits provided to Executive under Section 4.4.3(i) shall offset the benefits to be provided to Executive under Section 4.4.3(ii) and shall be deemed to have been provided to Executive pursuant to
Section 4.4.3(ii). 
 4.4.4    Equity Award Acceleration. 

(i)    Not in Connection With a Change in Control. In the event that the Executive’s employment is
terminated without Cause or for Good Reason and Section 4.4.4 (ii) below does not apply, the vesting of any equity awards granted to Executive that vest solely subject to Executive’s continued services to the Company (the
“Time-Based Vesting Equity Awards”) shall be deemed vested and immediately exercisable (if applicable) by the Executive with respect to such number of shares as determined in accordance with their applicable vesting schedules
as if Executive had provided an additional twelve (12) months of services as of the 

  
 8. 








 
date of termination. Treatment of any performance based vesting equity awards will be governed solely by the terms of the agreements under which such awards were granted and will not be eligible
to accelerate vesting pursuant to the foregoing provision. 
 (ii)    In Connection With a Change in
Control. In the event that the Executive’s employment is terminated without Cause or for Good Reason within the three (3) months immediately preceding or during the eighteen (18) months immediately following a Change in Control of
the Company (as defined in Section 4.5.4 of this Agreement), the vesting of any Time-Based Vesting Equity Awards granted to Executive shall be fully accelerated such that on the effective date of such termination (or if later, the date of the
Change in Control) one hundred percent (100%) of any Time-Based Vesting Equity Awards granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive. Treatment of any performance
based vesting equity awards will be governed solely by the terms of the agreements under which such awards were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision. 

(iii)    Release and Waiver. Any equity vesting acceleration pursuant to this Section 4.4.4 shall be
conditioned upon and subject to the Executive’s delivery to the Company of a fully effective Release in accordance with the terms specified by Section 4.4.3 hereof and such vesting acceleration benefit shall be in addition to the benefits
provided by Section 4.4.3 hereof. 
 4.5    Definitions. For purposes of this Agreement, the
following terms shall have the following meanings: 
 4.5.1    Complete Disability. “Complete
Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, because the Executive has become permanently disabled within the
meaning of any policy of disability income insurance covering employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Executive becomes
disabled, the term “Complete Disability” shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or
mental, which the Board, based upon medical advice or an opinion provided by a licensed physician, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, with or
without reasonable accommodation, for a period of at least one hundred eighty (180) days during any twelve (12) month period that need not be consecutive. 

4.5.2    Good Reason. “Good Reason” for the Executive to terminate the
Executive’s employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: 

(i)    a material reduction in the Executive’s duties, authority, or responsibilities relative to the duties,
authority, or responsibilities in effect immediately prior to such reduction, including by way of example, having the same title, duties, authority and responsibilities at a subsidiary level following a Change in Control; 

  
 9. 








 (ii)    the relocation of the Executive’s primary work location
to a point more than thirty-five (35) miles from the Executive’s current work location set forth in Section 1.5 that requires a material increase in Executive’s one-way driving distance;

 (iii)    a material reduction by the Company of the Executive’s base salary or annual target Bonus
opportunity, without the written consent of the Executive, as initially set forth herein or as the same may be increased from time to time pursuant to this Agreement; and 

(iv)    a material breach by the Company of Section 1.2 of this Agreement. 

Provided, however that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if (i) the Company is
given written notice from the Executive within sixty (60) days following the first occurrence of the condition that she considers to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy such condition
within thirty (30) days following such written notice, and (ii) the Executive terminates employment within thirty (30) days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. 
 4.5.3    Cause. “Cause” for the Company to
terminate Executive’s employment hereunder shall mean the occurrence of any of the following events, as determined reasonably and in good faith by the Board or a committee designated by the Board: 

(i)    the Executive’s gross negligence or willful failure to substantially perform her duties and
responsibilities to the Company or willful and deliberate violation of a Company policy; 
 (ii)    the
Executive’s conviction of a felony or the Executive’s commission of any act of fraud, embezzlement or dishonesty against the Company or involving moral turpitude that is likely to inflict or has inflicted material injury on the business of
the Company, to be determined by the sole discretion of the Company; 
 (iii)    the Executive’s
unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party that the Executive owes an obligation of nondisclosure as a result of the Executive’s relationship with the Company; and 

(iv)    the Executive’s willful and deliberate breach of the obligations under this Agreement that causes
material injury to the business of the Company. 
 4.5.4    Change in Control. For purposes of this
Agreement, “Change in Control” means: (i) a sale of all or substantially all of the assets of the Company; (ii) a merger or consolidation in which the Company is not the surviving entity and in which the holders of
the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the entity surviving such transaction or, where
the surviving entity is a wholly-owned subsidiary of another entity, the surviving entity’s parent; (iii) a reverse merger in which the Company is 

  
 10. 








 
the surviving entity but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities of
the surviving entity’s parent, cash or otherwise, and in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty
percent (50%) of the voting power of the Company or, where the Company is a wholly-owned subsidiary of another entity, the Company’s parent; or (iv) an acquisition by any person, entity or group (excluding any employee benefit plan, or
related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership of securities of the Company representing at least seventy-five percent (75%) of the combined
voting power entitled to vote in the election of Directors; provided, however, that nothing in this paragraph shall apply to a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.

 4.6    Application of Internal Revenue Code Section 409A. Notwithstanding anything
to the contrary set forth herein, any payments and benefits provided under this Agreement (the “Severance Benefits”) that constitute “deferred compensation” within the meaning of Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”) shall
not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation
Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the
additional 20% tax under Section 409A. 
 It is intended that each installment of the Severance Benefits payments provided for in this
Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A¬2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the
greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company (or, if applicable, the successor entity thereto) determines that the Severance Benefits constitute “deferred compensation” under Section 409A and Executive is,
on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the
adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of: (i) the date that is six months and one day after Executive’s Separation From Service,
or (ii) the date of Executive’s death (such applicable date, the “Specified Employee Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum
amount equal to the sum of the Severance Benefit payments that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant
to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement. 

Notwithstanding anything to the contrary set forth herein, Executive shall receive the Severance Benefits described above, if and only if
Executive duly executes and returns to the 

  
 11. 








 
Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Company’s standard form of release of claims in
favor of the Company (attached to this Agreement as Exhibit A) (the “Release”) and permits the release of claims contained therein to become effective in accordance with its terms (such latest permitted date, the
“Release Deadline”). If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in
which Executive separates from service, the Release will not be deemed effective any earlier than the Release Deadline. Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise
delivered prior to the effective date (or deemed effective date) of the Release. Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll
pay day following the effective date of the Release, the Company will pay Executive the Severance Benefits Executive would otherwise have received under the Agreement on or prior to such date but for the delay in payment related to the effectiveness
of the Release, with the balance of the Severance Benefits being paid as originally scheduled. 
 The severance benefits are intended to
qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly.

 4.7    Application of Internal Revenue Code Section 280G. If any payment or benefit
Executive would receive pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and
(ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount”
shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking
into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an
after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute
payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic
benefit, the items so reduced will be reduced pro rata. 
 In the event it is subsequently determined by the Internal Revenue Service that
some portion of the Reduced Amount as determined pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the
Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to
the preceding sentence. 

  
 12. 








 Unless Executive and the Company agree on an alternative accounting firm, the accounting firm
engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or
auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the
determinations by such accounting firm required to be made hereunder. 
 The Company shall use commercially reasonable efforts to cause the
accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive’s
right to a Payment is triggered (if requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. 

4.8    Indemnification Agreements. Concurrently with the execution of this Agreement, the Company and the
Executive shall enter into indemnification agreements, copies of which are attached hereto as Exhibit B-1 and Exhibit B-2. 

4.9    Confidential Information and Invention Assignment Agreement. The Executive shall execute the
Company’s Confidential Information and Invention Assignment Agreement the terms of which shall govern the terms of Executive’s employment following the Effective Date, and a copy of which is attached as Exhibit C. 

4.10    No Mitigation or Offset. The Executive shall not be required to seek or accept other employment, or
otherwise to mitigate damages, as a condition to receipt of the Severance Benefits, and the Severance Benefits shall not be offset by any amounts received by the Executive from any other source, except to the extent that the Executive’s rights
to the benefits described in Sections 4.4.3(i)(b) or 4.4.3(ii)(c), as applicable, are terminated by reason of the Executive obtaining full-time employment with another company or business entity which offers comparable health insurance coverage.

  

	5.	Assignment and Binding Effect. 

 This Agreement shall be binding upon the Executive and
the Company and inure to the benefit of the Executive and the Executive’s heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the Executive’s duties
under this Agreement, neither this Agreement nor obligations under this Agreement shall be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal
representatives, provided that the Agreement may only be assigned to an acquirer of all or substantially all of the Company’s assets. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement
for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the
assets or business of the Company. 

  
 13. 









	6.	Notice. 

 For the purposes of this Agreement, notices, demands, and all other forms of
communication provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or (unless otherwise specified) mailed by registered mail, return receipt requested, postage prepaid, or by confirmed
facsimile, addressed as set forth below, or to such other address as any party may have furnished to the other in writing in accordance herewith, except that notices of address shall be effective only upon receipt, as follows: 

If to the Company: 
 Horizon
Pharma, Inc. 
 150 S. Saunders Rd. 

Lake Forest, IL 60045 
 Attention:
Timothy P. Walbert, Chairman, President & CEO 
 Fax:
847-572-1372 
 If to the Executive: 

1111 Evergreen Dr. 
 Lake Forest,
IL 60045 
 Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or five (5) days
after its deposit in the United States mail as specified above. Either Party may change its address for notices by giving written notice to the other Party in the manner specified in this section. 

 

	7.	Choice of Law. 

 This Agreement shall be governed by the laws of the State of Illinois,
without regard to any conflicts of law principals thereof that would call for the application of the laws of any other jurisdiction. The Parties consent to the exclusive jurisdiction and venue of the federal court in the Northern District of
Illinois, and state courts located in the state of Illinois, county of Cook. Nothing in this Section 7 limits the rights of the Parties to seek appeal of a decision of an Illinois court outside of Illinois that has proper jurisdiction over the
decision of a court sitting in Illinois. 
  

	8.	Integration. 

 This Agreement, including Exhibit A, Exhibit B-1 and B-2, Exhibit C, the 2014 Equity Incentive Plan and the Equity Plan Documents, contains the complete, final and exclusive agreement of the Parties relating to the terms
and conditions of the Executive’s employment and the termination of Executive’s employment, and supersedes all prior and contemporaneous oral and written employment agreements or arrangements between the Parties. 

 

	9.	Amendment. 

 This Agreement cannot be amended or modified except by a written agreement
signed by the Executive and the Company. 

  
 14. 









	10.	Waiver. 

 No term, covenant or condition of this Agreement or any breach thereof shall be
deemed waived, except with the written consent of the Party against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or
any other term, covenant, condition or breach. 
  

	11.	Severability. 

 The finding by a court of competent jurisdiction of the unenforceability,
invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or
provision with a valid and enforceable term or provision, which most accurately represents the Parties’ intention with respect to the invalid, unenforceable, or illegal term or provision. 

 

	12.	Interpretation; Construction. 

 The headings set forth in this Agreement are for
convenience of reference only and shall not be used in interpreting this Agreement. This Agreement has been drafted and negotiated by legal counsel representing the Company and the Executive. The Parties acknowledge that each Party and its counsel
has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this
Agreement. 
  

	13.	Execution by Facsimile Signatures and in Counterparts. 

 The parties agree that facsimile
signatures shall have the same force and effect as original signatures. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

  

	14.	Survival. 

 The provisions of this Agreement, and of all other agreements referenced
herein, shall survive the termination of this Agreement, and of the Executive’s employment by the Company for any reason, to the extent necessary to enable the parties to enforce their respective rights hereunder. 

[Remainder of Page Intentionally Left Blank] 

  
 15. 








 IN WITNESS WHEREFORE, the parties have signed this Agreement on the date first written
above. 
 HORIZON PHARMA, INC. 
 HORIZON PHARMA USA,
INC. 
 By: 
 Title: Chairman, President & CEO

 Print Name: Timothy P. Walbert 
  

	
	 /s/ Timothy P. Walbert


 Signature: 
 As
authorized agent of the Company 
 EXECUTIVE: 
 SHAO-LEE LIN 
  

	
	 /s/ Shao-Lee Lin

	Shao-Lee Lin, individually


  
 16.